Lilly to buy injectable drug plant in manufacturing ramp-up
Nexus Pharmaceuticals Launches Baclofen Injection, USP
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals LLC announced that the U.S. Food and Drug Administration (FDA) issued a notice in the Federal Register that ephedrine sulfate should not be bulked by compounding facilities. Bulking is the practice of an outsourcing facility to “compound a drug using a bulk drug substance.”1 The FDA explained that bulk compounding is allowed only where there is a drug shortage or “the bulk drug substance appears on a list” set by the FDA called “the 503B Bulks List.”2 Section 503B refers to the portion of the Drug Quality and Security Act setting forth requirements when certain compounded products may be allowed.
Nexus' Generic Sodium Chloride Receives Approval in the U.S.
Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride for Injection Concentrate, USP
Nexus' Generic Potassium Chloride Receives Approval in the U.S.
Nexus Pharmaceuticals Receives FDA Approval for Sterile Water for Injection, USP
Nexus' Generic Sterile Water for Injection Receives Approval in the U.S.